Background: Helicobacter pylori (Hp) eradication fails in about 10% of patients because of the occurrence of resistance to antibiotics and side-effects. During anti H.pylori therapy, probiotics have been used to reduce the incidence of side-effects.
Objectives: To determine whether adding the probiotic Lactobacillus rhamhousus GG to an anti-H. pylori regimen could help to prevent or minimize the gastrointestinal side-effect burden.
Material And Methods: 66 subjects screening positive for H. pylori infection (male/female: 45/21, mean age 56,6 DS ± 16,7 year ), 59 subjects receiving 7 days of Omeprazole 20 mg b.i.d, Amoxicillin 1000 mg b.i.d and Clarithromycin 500 mg b.i.d were randomly assigned to Lactobacillus rhamnosus GG (6 x 9 ufc b.i.d ) (n = 29) or placebo (n = 30). Patients completed questionnaires after the treatment to determine the type and 10 severity of side-effects.
Results: Side effects occurred mainly during the eradication therapy; none of them caused therapy discontinuation. Bloating, diarrhea, taste disturbance and epigastric discomfort were the most frequent side effects: (10.3% versus 16%, 13.8% versus 20%, 13.7% versus 20% and 13.7 % versus 20% respectively). No significant differences were found between the two groups for individual symptoms.
Conclusion: In this study, probiotic supplementation did not diminish significantly the frequency of new or aggravated symptoms during H. pylori eradication.
Download full-text PDF |
Source |
---|
Background Aims: SBP leads to high rates acute kidney injury (AKI) -hepatorenal syndrome and mortality. Population-based studies on contemporary SBP epidemiology are needed to inform care. In a large, national cohort of patients diagnosed with SBP and confirmed by ascitic fluid criteria, we characterized ascitic fluid characteristics, in-hospital and 12-month mortality, AKI, and recurrent SBP.
View Article and Find Full Text PDFJ Clin Oncol
January 2025
Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of China, Shatin, Hong Kong Special Administrative Region, China.
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.
View Article and Find Full Text PDFJ Speech Lang Hear Res
January 2025
Speech-Language-Hearing Center, School of Foreign Languages, Shanghai Jiao Tong University, China.
Purpose: Neurotypical individuals show a robust "global precedence effect (GPE)" when processing hierarchically structured visual information. However, the auditory domain remains understudied. The current research serves to fill the knowledge gap on auditory global-local processing across the broader autism phenotype under the tonal language background.
View Article and Find Full Text PDFIntegr Environ Assess Manag
January 2025
Henkel AG & Co KGaA, Düsseldorf, Germany.
The assessment of humans indirectly exposed to chemicals via the environment (HvE) is an assessment element of the Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) regulation. The European Union System for the Evaluation of Substances (EUSES) is the default screening tool, aimed at prioritizing chemicals for further refinement/higher tier assessment. This review summarizes the approach used in EUSES, evaluates the state of the science in human exposure modeling via the environment, and identifies areas for further research to strengthen the confidence and applicability of EUSES for assessing HvE.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Pediatrics, University of Washington, Seattle, Washington, United States of America.
Aim: To evaluate the impact of heart rate-guided basic resuscitation compared to Helping Babies Breathe on neonatal outcomes and resuscitation practices in the Democratic Republic of the Congo.
Methods: We conducted a pre-post clinical trial comparing heart rate-guided basic resuscitation to Helping Babies Breathe in three facilities, enrolling in-born neonates ≥28 weeks gestation. We collected observational data during a convenience sample of resuscitations and extracted clinical data from the medical record for all participants.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!